Floatz Rating
BB66/100
Confidence
Indicative
Sponsor
Bayer
Modality
UNKNOWN
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
59High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05022758CT.gov A Study to Learn Whether There Are Differences in the Kidney's Ability to Work Properly in Korean Patients With Non-valvular Atrial Fibrillation (Irregular and Often Rapid Heartbeat Not Caused by a Heart Valve Problem) Treated With Rivaroxaban as Compared to Those Treated With Warfarin | — | Completed | — | — | — |
NCT04356989CT.gov Study to Gain Information on the Drug Xarelto for the Prevention of Brain Attack and Blockage of an Artery in the Non-central Nervous System Due to Irregular Heartbeat in Taiwanese Patients Suffering From Decreased Renal Function | — | Completed | — | — | — |
NCT03887780CT.gov A Study to Evaluate the Safety and Effectiveness of Rivaroxaban (Xarelto) for Prevention of Stroke and Systemic Embolism in Indian Patients With Non-valvular Atrial Fibrillation (NVAF) | — | Completed | — | — | — |
NCT03847181CT.gov Study to Learn More About the Benefits and Side-effects of Drugs Rivaroxaban and Apixaban Compared to the Drug Warfarin for Stroke Prevention in Patients With Rapid and Irregular Heartbeat Which is Not Due to a Heart-valve Fault (Non-valvular Atrial Fibrillation) in the UK Routine Clinical Practice | — | Completed | — | — | — |
NCT03746301CT.gov Xarelto on Prevention of Stroke and Non-Central Nervous Systemic Embolism in Renally Impaired Korean Patients With Non-valvular Atrial Fibrillation | — | Completed | — | — | — |
NCT03563937CT.gov Real-world Comparative Effectiveness of Stroke Prevention in Patients With Atrial Fibrillation Treated With Factor Xa Non-vitamin-K Oral Anticoagulants (NOACs) vs. Phenprocoumon | — | Completed | — | — | — |
NCT03374540CT.gov Rivaroxaban vs Warfarin for SPAF in Multi-morbid Patients | — | Completed | — | — | — |
NCT03284762CT.gov Xarelto on Prevention of Stroke and Noncentral Nervous System Systemic Embolism in Treatment-naïve Asian Patients With Non-valvular Atrial Fibrillation | — | Completed | — | — | — |
NCT03242278CT.gov Real-world Dosing Patterns of Rivaroxaban in the United States | — | Completed | — | — | — |
NCT02690155CT.gov Real-world Comparative Effectiveness of Rivaroxaban Versus VKA | — | Completed | — | — | — |
Show 15 more trialsShow fewer
NCT02468102CT.gov Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Sweden) | — | Completed | — | — | — |
NCT03462446CT.gov Analysis of the Potential Savings of Rivaroxaban Events Versus Vitamin K Antagonists Events | — | Completed | — | — | — |
NCT02485873CT.gov Real-Life Evidence on Stroke Prevention in SPAF | — | Completed | — | — | — |
NCT02262676CT.gov Observational Study to Assess Sociodemographic and Clinical Features of Patients Treated With Rivaroxaban in Routine Clinical Practice of Hematologists, Cardiologists and Internists of Spain | — | Completed | — | — | — |
NCT01839357CT.gov Exploring the Efficacy of Once Daily Oral Rivaroxaban for Treatment of Thrombus in Left Atrial/Left Atrial Appendage in Subjects With Nonvalvular Atrial Fibrillation or Atrial Flutter | — | Completed | — | — | — |
NCT01855139CT.gov Belgian Real Life Non-interventional Study (NIS) on Xarelto in Non-valvular Atrial Fibrillation (AF) Patients Treated for the Prevention of Stroke and Systemic Embolism | — | Completed | — | — | — |
NCT01805531CT.gov Satisfaction/Quality of Life With Rivaroxaban in SPAF (Stroke Prevention in Atrial Fibrillation) Indication | — | Completed | — | — | — |
NCT01800006CT.gov Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation in Latinamerica and EMEA Region | — | Completed | — | — | — |
NCT01750788CT.gov Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation in Asia | — | Completed | — | — | — |
NCT01674647CT.gov Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion | — | Completed | — | — | — |
NCT01606995CT.gov Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation | — | Completed | — | — | — |
NCT01947985CT.gov Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (Netherlands) | — | Completed | — | — | — |
NCT01947959CT.gov Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Germany) | — | Completed | — | — | — |
NCT01947998CT.gov Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (UK) | — | Completed | — | — | — |
NCT00494871CT.gov Efficacy and Safety of Rivaroxaban for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Atrial Fibrillation
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Bay 59-7939 (this asset) | Bayer | P3 | BB · 66 |
| Edoxaban | National Taiwan University Hospital | P4 | A |
| Rivaroxaban | VA Office of Research and Development | P4 | BBB |
| Dabigatran | Pfizer | P4 | BBB |
| Apixaban | Regeneron Pharmaceuticals | P4 | BBB |
| Warfarin | Pfizer | P4 | BBB |
| Aspirin | Yonsei University | P4 | BBB |
| 3-(.ALPHA.-ACETONYL-P-NITROBENZYL)-4-HYDROXYCOUMARIN | University of Edinburgh | P4 | BB |
| Tirzepatide | Ali Aminian | P4 | BB |
+32 more in the Atrial Fibrillation cohort
Other indications for Bay 59-7939
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Stroke Disorder | — | P3 | CCC · 52 |
| Pulmonary Embolism | — | Unk | D · 30 |
| Acute Coronary Syndrome | — | Unk | D · 30 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Bay 59-7939 in Atrial Fibrillation. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/bay-59-7939-atrial-fibrillation
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →